|
Commission Européenne
|
|
AbbVie
|
|
Amgen
|
|
Bayer
|
|
BMS
|
|
Celgene
|
|
CSL Behring
|
|
CSL Behring (Congrès)
|
|
Edwards Lifescience SA
|
|
EFPIA
|
|
Eli Lilly
|
|
Gilead Sciences Europe
|
|
Grunenthal
|
|
GSK
|
|
Janssen
|
|
Medicines for Europe
|
|
MSD
|
|
Novartis Group
|
|
Novartis Pharma AG
|
|
Novartis Sandoz
|
|
Pfizer Inc
|
|
Pfizer SA
|
|
F. Hoffman-La Roche
|
|
Sanofi Aventis
|
|
Servier
|
|
Shire
|
|
Takeda
|
|
UCB
|
|
Vertex
|
|
|
|
Membres
|
|
|
- €
|
|
45,000.00 €
|
|
35,000.00 €
|
|
10,000.00 €
|
|
75,000.00 €
|
|
15,000.00 €
|
|
10,000.00 €
|
|
10,000.00 €
|
|
25,000.00 €
|
|
7,500.00 €
|
|
15,000.00 €
|
|
64,034.40 €
|
|
10,000.00 €
|
|
30,000.00 €
|
|
60,000.00 €
|
|
27,500.00 €
|
|
100,000.00 €
|
|
20,000.00 €
|
|
32,545.00 €
|
|
20,000.00 €
|
|
26,000.00 €
|
|
30,000.00 €
|
|
50,000.00 €
|
|
50,000.00 €
|
|
15,000.00 €
|
|
10,000.00 €
|
|
40,000.00 €
|
|
30,000.00 €
|
|
50,000.00 €
|
|
|
|
20,450.00 €
|
|
|
0.0%
|
|
2.1%
|
|
1.6%
|
|
0.5%
|
|
3.5%
|
|
0.7%
|
|
0.5%
|
|
0.5%
|
|
1.2%
|
|
0.4%
|
|
0.7%
|
|
3.0%
|
|
0.5%
|
|
1.4%
|
|
2.8%
|
|
1.3%
|
|
4.7%
|
|
0.9%
|
|
1.5%
|
|
0.9%
|
|
1.2%
|
|
1.4%
|
|
2.4%
|
|
2.4%
|
|
0.7%
|
|
0.5%
|
|
1.9%
|
|
1.4%
|
|
2.4%
|
|
|
|
1.0%
|
|
|
Name of company/funder
|
Contribution to the CBP
|
% of total income
|
|
Alexion
|
20,000.00 €
|
0.9%
|
|
Amgen
|
5,000.00 €
|
0.2%
|
|
Baxter
|
10,000.00 €
|
0.5%
|
|
Biogen
|
15,000.00 €
|
0.7%
|
|
EFPIA (DSL)
|
3,982.02 €
|
0.2%
|
|
ENHA
|
10,000.00 €
|
0.5%
|
|
GSK
|
70,000.00 €
|
3.3%
|
|
Kyowa Kirin
|
10,000.00 €
|
0.5%
|
|
Merck
|
30,000.00 €
|
1.4%
|
|
Microsoft
|
30,000.00 €
|
1.4%
|
|
MNI (Medical Nutrition International)
|
20,000.00 €
|
0.9%
|
|
Novartis Pharma AG ONCO
|
30,000.00 €
|
1.4%
|
|
Novo Nordisk
|
30,000.00 €
|
1.4%
|
|
Shire
|
5,000.00 €
|
0.2%
|
|
Vaccines Europe / EFPIA
|
75,000.00 €
|
3.5%
|
|
Vertex
|
15,000.00 €
|
0.7%
|
|
